Relay Therapeutics (RLAY) Assets Average (2020 - 2026)

Relay Therapeutics (RLAY) has 7 years of Assets Average data on file, last reported at $660.5 million in Q1 2026.

• On a quarterly basis, Assets Average fell 20.93% year-over-year to $660.5 million in Q1 2026; TTM through Mar 2026 was $660.5 million, a 20.93% decrease from a year earlier, with the FY2025 full-year figure at $746.3 million, down 12.98% from the prior year.
• Assets Average for Q1 2026 stood at $660.5 million, up from $645.7 million in the prior quarter.
• Over the last five years, Assets Average for RLAY reached as high as $1.1 billion in Q4 2022 and fell as low as $645.7 million in Q4 2025.
• Historically, Assets Average has averaged $879.3 million across 5 years, with a median of $875.5 million in 2023.
• Across the five-year window, Assets Average surged 155348.56% in 2022 and fell 28.32% in 2025, its largest moves.
• Year by year, Assets Average stood at $1.1 billion in 2022, then retreated by 22.81% to $875.5 million in 2023, then gained by 2.88% to $900.7 million in 2024, then decreased by 28.32% to $645.7 million in 2025, then increased by 2.29% to $660.5 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $660.5 million in Q1 2026, $645.7 million in Q4 2025, and $699.4 million in Q3 2025.